Overall effi cacy of HPV-16/18 AS04-adjuvanted vaccine
against grade 3 or greater cervical intraepithelial neoplasia:
4-year end-of-study analysis of the randomised,
double-blind PATRICIA trial; Cross-protective effi cacy of HPV-16/18 AS04-adjuvanted
vaccine against cervical infection and precancer caused by
non-vaccine oncogenic HPV types: 4-year end-of-study
analysis of the randomised, double-blind PATRICIA trial